Lenalidomide Glenmark

Lenalidomide, the active ingredient in Lenalidomide Glenmark, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) chromosome abnormality in adult patients.

GNH USA supplies Lenalidomide Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders. - Multiple Myeloma: improves progression‑free survival and disease control in adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and corrects cytopenias.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Diarrhea: loose stools occurring during treatment. - Constipation: reduced bowel movements. - Rash: mild skin eruptions. - Nausea: feeling of sickness. - Peripheral neuropathy: tingling or numbness in extremities.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophil count increasing infection risk. - Severe thrombocytopenia: dangerously low platelet levels causing bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: significant liver enzyme elevation or injury. - Hypersensitivity reactions: severe allergic responses including Stevens‑Johnson syndrome.

Before initiating lenalidomide, several safety considerations should be reviewed. - Pregnancy contraindication: drug is category X and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Renal impairment: adjust dose or monitor closely in patients with reduced kidney function. - Drug interaction awareness: review concomitant medications for potential interactions. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide has notable interactions that may require dose adjustment or avoidance.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin): decrease lenalidomide exposure. - Thalidomide: combined use raises risk of teratogenicity and peripheral neuropathy. - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Live vaccines: immunosuppression can reduce vaccine efficacy and increase infection risk.

Moderate Interactions (Monitor Closely): - NSAIDs: may exacerbate neutropenia or thrombocytopenia. - Antihypertensives: possible alterations in blood pressure control. - CYP2C19 inhibitors (e.g., fluoxetine): modest increase in lenalidomide levels. - Proton pump inhibitors: may affect absorption in some patients. - Herbal supplements (e.g., St. John’s wort): potential induction of metabolic pathways.